Clinical Trials Browser

Phase 1/2 × amivantamab × 90 days × Clear all

NCT05488314 2026-03-13

METalmark

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05908734 2026-03-13

PolyDamas

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07227025 2026-03-13

KaRAnaSa

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06083857 2026-03-11

PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05845671 2026-01-14

Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms